A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

NCT01965613 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pyoderma Gangrenosum

Interventions

BIOLOGICAL: Xilonix

Sponsor

Janssen Research & Development, LLC